Novo Nordisk reveals post-hoc cardiovascular data for semaglutide

No­vo Nordisk bol­stered its heart dis­ease da­ta for semaglu­tide on Fri­day with ad­di­tion­al analy­ses from a hand­ful of tri­als.

In a pooled analy­sis of cer­tain …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.